Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: A phase I and drug incorporation study

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 31-40

  Eisbruch, Avraham ^a   Robertson, John M ^a   Johnston, Carolyn M ^a   Tworek, Joseph ^a   Reynolds, Kevin R ^a   Roberts, James A ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAXIMUM ALLOWABLE CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; RECTUM BIOPSY; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 0032920567     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.31     Document Type: Article

References (39)

1. Montana GS, Fowler WC, Varia MA: Carcinoma of the cervix stage III: Results of radiation therapy. Cancer 57:148-154, 1986
2. Perez CA, Camel HM, Kuske RR, et al: Radiation therapy alone in the treatment of carcinoma of the uterine cervix: A 20-year experience. Gynecol Oncol 23, 127-140, 1986
3. Jampolis S, Andras EJ, Fletcher GH: Analysis of sites and causes of failure of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology 115:681-685, 1975
4. Thomas G, Dembo A, Fyles A, et al: Concurrent chemoradiation in advanced cervix cancer. Gynecol Oncol 38:446-451, 1990
5. Shueng PW, Hsu WL, Jen YM, et al: Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 40:889-896, 1998
6. Grigsby PW: Lack of proven efficacy of chemotherapy for patients with carcinoma of the uterine cervix. Semin Radiat Oncol 4:30-33, 1994
7. Stehman FB, Bundy BN, Thomas G, et al: Hydroxyurea versus misonidazole with radiation in cervical carcinoma. J Clin Oncol 11:1523-1528, 1993
8. Rose P, Bundy B, Thigpen J, et al: Significant preliminary results of a phase III randomized study of concomitant chemotherapy with weekly cisplatin vs hydroxyurea, 5-fluorouracil infusion and bolus cisplatin vs hydroxyurea in advanced cervical cancer: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 17:360a, 1998 (abstr)
9. Lin JC, Ho ESC, Jan JS, et al: High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 61:101-108, 1996
10. Wong LC, Choo YC, Choy D, et al: Long-term follow-up of potentiation of radiotherapy by cisplatinum in advanced cervical cancer. Gynecol Oncol 35:159-163, 1989
11. McGinn CJ, Scewach DS, Lawrence TS: Radiosensitizing nucleosides. J Natl Cancer Inst 88:1193-1203, 1996
12. Bagshaw MA, Doggette RLS, Smith KC, et al: Intraarterial 5-bromodeoxyuridine and X-ray therapy. AJR Am J Roentgenol 99:886-894, 1967
13. Lawrence TS, Davis MA, Maybaum J, et al: The potential superiority of hromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res 52:3698-3704, 1992
14. Lawrence TS, Davis MA, Stetson PL, et al: Kinetics of broinodeoxyuridine elimination from human colon cancer cells in vitro and in vivo. Cancer Res 54:2964-2968, 1994
15. Rotenberg AD, Bruce WR, Baker RG: Incorporation of 5-iodode-oxyuridine 1-131 in spontaneous C3H mouse mammary tumors. Br J Radiol 35:337-342, 1962
16. Clifton KH, Szybalski W, Heidelberger C, et al: Incorporation of I-125-labeled iododeoxyuridine into the deoxyribonucleic acid of murine and human tissues following therapeutic doses. Cancer Res 23:1715-1723, 1963
17. International Commission on Radiation Units and Measurements. Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology. ICRU Report No. 38.Washington. DC. International Commission on Radiation Units and Measurements, 1985
18. Eisbruch A, Johnston CM, Mattel MK, et al: Customized gynecologic interstitial implants: CT-based planning, dose evaluation, and optimization aided by laparotomy. Int J Radiat Oncol Biol Phys 40:1087-1093, 1998
19. Maybaum J, Kott MJ, Johnston NJ, et al: Analysis of bromodeoxyuridine incorporation into DNA: Comparison of gas chromatographic/mass spectrometric. CsCl gradient sedimentation, and specific radioactivity methods. Anal Biochem 161:164-171, 1987
20. Beisker W, Dolbeare F, Gray JW: An improved immunocytochemical procedure for high sensitivity detection of incorporated bromodeoxyuridine. Cytometry 8:235-239, 1987
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 78:427-481, 1958
22. Mitchell JB, Kinsella TJ, Russo A, et al: Radiosensitization of hematopoietic precursor cells in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine. Int J Radiat Oncol Biol Phys 457-463, 1983
23. Robertson JM, Ensminger WD, Walker S, et al: A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic-cancer. Int J Radiat Oncol Biol Phys 37:331-335, 1997
24. Goffman T, Tochner Z, Glatstein E: Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer 67:572-576, 1991
25. Robertson JM, Sondak VK, Weiss SA, et al: Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 31:87-92, 1995
26. Sondak VK, Stetson PL, McKeever PE, et al: IUdR incorporation and washout in normal human tissue after i.v. infusion. Proc Am Assoc Cancer Res 33:2985, 1992 (abstr)
27. Kinsella TJ, Mitchell JB, Russo A, et al: Continuous infusions of bromodeoxyuridine as a clinical radiosensitizer. J Clin Oncol 2:1144-1150, 1984
28. Urtasun RC, Cosmatos D, DelRowe J, et al: Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: A comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 27:207-214, 1993
29. Thoms WW, Eifel PJ, Smith TL, et al: Bulky endocervical carcinoma: A 23-year experience. Int J Radiat Oncol Biol Phys 23:491-499, 1992
30. Fields AL, Anderson PS, Goldberg GL, et al: Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 61:416-422, 1996
31. Lawrence TS, Davis MA, Maybaum J, et al: The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 18:1393-1398, 1990
32. Kinsella TJ, Dobson PP, Mitchell JB, et al: Enhancement of X ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13:733-739, 1987
33. Ling LL, Ward JF: Radiosensitization of Chinese hamster V79 cells by bromodeoxyuridine substitution of thymidine: Enhancement of radiation-induced toxicity and DNA strand break production by monofilar and bifilar substitution. Radiat Res 121:76-83, 1990
34. Phillips TL, Bodell WJ, Uhl V, et al: Correlation of exposure time, concentration and incorporation of IdUrd in V-79 cells with radiation response. Int J Radiat Oncol Biol Phys 16:1251-1255, 1989
35. Lawrence TS, Chang EY, Davis MA, et al: Effect of irradiation on bromodeoxyuridine incorporation in human colon cancer xenografts. Int J Radiat Oncol Biol Phys 34:617-621, 1996
36. Pearcy RG, Stuart GCE, MacLean GD, et al: Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 58:34-41, 1995
37. John M, Flam M, Caplan R, et al: Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15. Gynecol Oncol 61:221-226, 1996
38. Roberts WS, Hoffman MS, Kavanagh JJ, et al: Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract. Gynecol Oncol 43:233-236, 1991
39. Poot M, Schuster A, Hoehn H: Cytostatic synergism between bromodeoxyuridine, bleomycin, cisplatin and chlorambucil demonstrated by a sensitive cell kinetic assay. Biochem Pharmacol 41:1903-1909, 1991